REPROCELL News

Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease

15 March 2021

NEW YORK, March 11, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a partnership agreement with REPROCELL, a contract research organization (CRO), providing a unique combination of products and services to power translational research, to assess the effect of the HT-003 therapeutic platform on tissue from ulcerative colitis and Crohn’s disease patients. Fresh explants of ulcerative colitis and Crohn’s disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases. All testing will be performed by REPROCELL.  

Continue reading

eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations

16 July 2020

March 19, 2020

Continue reading

All posts

Stay informed

Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).

Recent REPROCELL News

News Items by Topic

© 2021 REPROCELL Inc. All rights reserved.

REPROCELL Inc.  日本語  MetLife Shin-yokohama Bldg. 9F, 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa 222-0033, Japan
REPROCELL USA Inc. 9000 Virginia Manor Road, Suite 207, Beltsville, 20705, USA
REPROCELL Europe Ltd. Thomson Pavilion, Todd Campus, West of Scotland Science Park, Acre Road, Glasgow, G20 0XA, United Kingdom
Bioserve Biotechnologies (India) PVT Ltd. Unit: D4-D7, 1st Floor, Industrial Estate, Moula Ali, Medchal-Malkajgiri Dist., Hyderabad-500040, Telangana, India